USFDA withdraws warning letter to Divi's Lab unit

Drug firm Divi's Laboratories today said the US health regulator has "closed out" a warning letter issued to a unit at Visakhapatnam following evaluation of corrective actions taken by the company at the plant.

"Divi's Laboratories has been informed by the USFDA that the agency has completed evaluation of the company's corrective actions in response to FDA's warning letter..dated April 13, 2017" the company said in a BSE filing.

"We also note from the update on FDA's website that they have closed-out the warning letter," it added.

TRENDING NOW

Dabur promoter Burman family announces Rs 2,116 crore open offer for 26% stake in Religare

Vivo T2 Pro 5G Review: Designed for powerful performance

Probuds 22 review: Lava's value offering in TWS segment

Amazon Great Indian Festival Sale 2023 likely to begin soon; discounts, exchange and bank offers, and more

India exporting 75,000 tonnes non-basmati rice to UAE

Flipkart Big Billion Days Sale: Credit card, Paytm offers on Mobile phones and more

Domestic capital goods firm announces expansion plan, to venture into Dubai market with Rs 500 million investment

A housing finance stock may be preparing to extend a rally that began in late March

India vs Australia 3rd ODI Free Live Streaming: When and How to watch IND VS AUS match live on Web, tv, mobile apps online

"Participate in the Chandrayaan 3 Maha Quiz on MyGov.in," ISRO Chief S Somnath

Retirement Planning: How to get Rs 1 lakh pension every month?

Updater Services IPO hits D-Street: Issue price, listing date, other key details

NPS Tier II Default Scheme: Flexibility, easy withdrawals, and no minimum balance; here's what makes it a smart choice

Karnataka Bank shares get a boost after lender approves raising up to Rs 1,500 crore via QIP

WhatsApp rolls out new feature 'who can add members' to community chats

Following the announcement, shares of the company rose by 2.80 per cent to Rs 1,038 apiece in morning session on BSE.

Last week, Divi's Laboratories had informed that the US health regulator would lift an import alert imposed on the company's Unit-II in Visakhapatnam and was moving to close out the warning letter issued to the unit.

The USFDA in March had issued import alert under clauses 99-32 and 66-40, and a warning letter later for the Visakhapatnam facility for non-compliance of good manufacturing practice (GMP) norms, the company had informed bourses earlier.

The company in July announced that USFDA had moved to lift Import Alert 99-32 imposed on the unit.

As per USFDA, an import alert under 66-40 entails "detention without physical examination" of drugs from firms which have not met drug GMPs, while alert under 99-32 is issued to "firms refusing FDA foreign establishment inspection".

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)